TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02574507

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Couples-Based Behavioral Weight and Symptom Management
Description: Investigators anticipate that the intervention developed in phase I will consist of a total of 12 sessions 90 minutes in length (18 therapy hours) spaced across approximately 5 months. Sessions are spaced to provide participants sufficient time to complete home practice exercises and adequately examine change in weight and maintenance of weight loss. Sessions will be conducted individually for each day. The first 6 sessions will occur weekly and the final 6 sessions will occur biweekly.
Study: NCT03095963

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: a mixture of highly charged Lactobacilli and Bifidobacteria (VSL#3®)
Description: Patients assigned to the study group took the probiotic supplement VSL#3® for two months, in addition to levothyroxine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levothyroxin
Description: replacement therapy for hypothyroidism

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levothyroxin
Description: replacement therapy for hypothyroidism
Study: NCT04341207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine 200 mg 3 times a day for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine 200 mg 3 times a day for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Azithromycin 500 mg on day 1 followed by 250 mg/day for 4 days
Study: NCT00871104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosfomycin and imipenem
Description: IV Fosfomycin 2 gr./6 hours and IV Imipenem 1 gr./6 hours adjusted acoording to renal function during 4-8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: IV Vancomycin 30 mg/kg twice a day with valley leves higher than 15 mcg/kg
Study: NCT04688814

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single puncture combined lumbar erector spinae plane block and quadrates lumborum block
Description: Patients will lay laterally with the fracture side independent, a curvilinear transducer will be placed in a parasagittal plane 3-4 cm lateral to the lumbar spinous process of L4.The probe is shifted slowly to the lateral side till the transverse processes disappear. After subcutaneous local infiltration with lidocaine 1% at the cephalic end of the probe, the block needle is advanced through the erector spinae and QL muscles, until it pierces the epimysium of the QL muscle. LA is injected anterior to the QL, between the QL and psoas muscles.~Then the caudal end of the probe is rotated slowly medially towards lumbar spine till the transverse process of L4 appears in the ultrasound image. The needle is withdrawn to subcutaneous tissue, then advanced in plane towards transverse process of L4. After contacting it, LA is deposited between transverse process and overlying ESM.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulfate
Description: Patients will receive GA and analgesia will be based on opioids mainly intravenous morphine
Study: NCT00881595

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemoradiotherapy Temozolomide
Description: Temozolomide: 75 mg/m2 five days per week during radiotherapy for 5 weeks.Temozolomide: 75 mg/m2 five days per week during radiotherapy for 5 weeks. Temozolomide should be taken orally 1 hour before each session of radiotherapy during weekdays (Monday through Friday). The dose will be determined using the body surface area (BSA) calculated at the beginning of the concurrent treatment. The BSA will be calculated from the height obtained at the pretreatment visit and the weight obtained before the first day of treatment. The concurrent treatment will last until the end of radiotherapy.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Proton therapy
Description: 50 cobalt gray equivalent(CGE), 25 daily fractions, 5 weeks (2 CGE/fx)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Proton Chemoradiotherapy followed by surgery
Description: Proton Chemoradiotherapy followed by surgery. Resection of tumor at 4-6 weeks post-treatment.
Study: NCT00359424

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV rt-PA alone
Description: Intravenous (IV) recombinant tissue plasminogen activator (rt-PA) is the only approved acute stroke therapy; Group one will receive the standard dose of IV rt-PA given over an hour.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: endovascular therapy
Description: Group two will receive a lower dose or the standard dose of IV rt-PA and then undergo an angiogram test (cerebral angiography) right after the medicine is given to check for blood clots. If a clot is not seen then no more treatment will be given. If a clot is seen, the neurointerventionalist will then choose a protocol approved endovascular treatment given directly in the brain artery that will be most effective in reopening the blocked artery. Endovascular therapy can be implemented with or without interarterial rt-PA use.
Study: NCT03758664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICP-192
Description: Drug: ICP-192 Dose levels will be escalated following accelerated titration and modified 3+3 dose escalation scheme,
Study: NCT02041819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: Nimotuzumab: 200mg,IV once a week for 6 weeks during chemotherapy (days 1,8,15,22,29,36).
Study: NCT02949973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: voclosporin
Study: NCT00695604

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo via MDI.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone
Description: Fluticasone MDI.
Study: NCT00894972

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation following lumbar disc surgery (discectomy)
Description: Exercise: walking, range of motion, and general trunk strengthening with or without specific trunk muscle motor control exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation following lumbar disc surgery (discectomy)
Description: Exercise: walking, range of motion, and general trunk strengthening with or without specific trunk muscle motor control exercises.
Study: NCT04849403

Intervention type: PROCEDURE
Group type: OTHER
Intervention: CTSP
Description: In all patients Carter Thomasson Suture Passer (CTSP) were used for closing fascial defect peroperatively
Study: NCT03440242

Intervention type: DEVICE
Intervention: JJVC Contact Lens
Description: etafilcon A with PVP DD

Intervention type: DEVICE
Intervention: JJVC Contact Lens
Description: etafilcon A with PVP DD

Intervention type: DEVICE
Intervention: Marketed Contact Lens
Description: nelfilcon A DD

Intervention type: DEVICE
Intervention: Marketed Contact Lens
Description: nelfilcon A DD
Study: NCT01701011

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coping intervention
Description: Positive reappraisal coping intervention
Study: NCT03228979

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Structured Semi-Interactive Stroke Prevention Package
Description: The intervention arm will receive a Structured Semi-Interactive Stroke Prevention Package including patient workbook, short messaging services and health education videos for a period of one-year in addition to standard of care as per current guidelines.
Study: NCT00648882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEVOTHYROXINE SODIUM TABLETS,
Description: 2x300mcg, single dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SYNTHROID® 300 mcg Tablets
Description: 2x300mcg, single dose fasting
Study: NCT01052480

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-Influenza Immune Plasma
Description: 2 units of plasma with high titer anti-influenza A or anti-influenza B antibodies at baseline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: All subjects will receive an anti-influenza antiviral (e.g., oseltamivir or zanamivir), but may include treatment with licensed antivirals in patient populations or at doses not covered in the package insert, or with medications available under a EUA. Standard care may also include antibiotics and other medications.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: All subjects will receive an anti-influenza antiviral (e.g., oseltamivir or zanamivir), but may include treatment with licensed antivirals in patient populations or at doses not covered in the package insert, or with medications available under a EUA. Standard care may also include antibiotics and other medications.
Study: NCT02859337

Intervention type: DRUG
Group type: OTHER
Intervention: UPA-ECx1
Description: Evaluating the pharmacodynamic and pharmacokinetic outcomes in obese women using 30mg of UPA-based EC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UPA-ECx1
Description: Evaluating the pharmacodynamic and pharmacokinetic outcomes in obese women using 30mg of UPA-based EC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UPA-ECx1
Description: Evaluating the pharmacodynamic and pharmacokinetic outcomes in obese women using 30mg of UPA-based EC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UPA-ECx2
Description: Evaluating the pharmacodynamic and pharmacokinetic outcomes in obese women using 60mg of UPA-based EC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UPA-ECx2
Description: Evaluating the pharmacodynamic and pharmacokinetic outcomes in obese women using 60mg of UPA-based EC
Study: NCT03920124

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Step and walk-based high intensity interval exercise
Description: Four hospital-based trials will include two step-based (3 x 20 sec with 120 sec rest, or 3 x 60 sec with 60 sec rest) and two walking-based (e.g. 3 x 60 sec with 60 sec rest or 3 x 180 sec with 180 sec rest) interval exercise protocols, in a randomised and counterbalanced order.~Unsupervised (At home) exercise intervention will incorporate patients' preferred stair and/or walking-based interval exercise (from those completed during hospital trials). Initially patients will complete their chosen protocol three days per week, and then gradually progress exercise load (i.e. reps, work-to-rest ratio, and/or sessions per week) as appropriate, to a maximum of 6 x 60 sec stepping / 5 x 180 sec walking, five times per week (i.e. maximum of \~30 min daily or \~150 min weekly).
Study: NCT02088762

Intervention type: PROCEDURE
Intervention: surgical excision
Description: comparison of safety margin 1 versus 2 cm

Intervention type: PROCEDURE
Intervention: surgical excision
Description: comparison of safety margin 1 versus 2 cm
Study: NCT02481089

Intervention type: OTHER
Intervention: validation group
Study: NCT04969679

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E. coli Nissle 1917 (Mutaflor®)
Description: Take 1 capsule per day in the morning from the first day to the fourth day and take 2 capsules per day from the fifth day to the end of the testing period.(for 8 weeks)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Take 1 capsule per day in the morning from the first day to the fourth day and take 2 capsules per day from the fifth day to the end of the testing period.(for 8 weeks)
Study: NCT01065961

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Decadron
Description: Decadron will be given at a dose of 0.2 mg/kg intraoperatively, followed by Decadron 4 mg. every 6 hours for 24 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Placebo saline will be given intraoperatively as well as 4 doses every 6 hours for 24 hours.
Study: NCT01041937

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cemented Tibia
Description: Total knee arthroplasty with cemented or cemented tibia, and post operative clinical outcome tracking

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cementless Tibia
Description: Assessing the clinical outcomes of the different type of fixation
Study: NCT00684216

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine
Description: 200 mg, BID, PO, QD until progression of disease

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine
Description: 200 mg, BID, PO, QD until progression of disease

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hormonal treatment (tamoxifen, exemestane, anastrozole or letrozole)
Description: either tamoxifen or aromatase inhibitor (exemestane, anastrozole or letrozole), QD, until progression of disease
Study: NCT02498665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSP-7888 Dosing Emulsion
Description: Dose escalation cohort: Patients will be administered escalating doses of DSP-7888 Dosing Emulsion intradermally or subcutaneously in accordance with the following regimen: once weekly for four weeks during the Induction Phase, once every 7 to 14 days for 6 weeks during the Consolidation Phase, and once every 14 to 28 days until a discontinuation criterion is met during the Maintenance Phase.~MDS cohort 1: Patients will be intradermally administered of DSP-7888 at 10.5 mg every week for 4 weeks, every 2 weeks until Week 24, and then every 4 weeks.~MDS cohort 2: Patients will be intradermally administered of DSP-7888 at 10.5 mg every 2 weeks until Week 24, and then every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSP-7888 Dosing Emulsion
Description: Dose escalation cohort: Patients will be administered escalating doses of DSP-7888 Dosing Emulsion intradermally or subcutaneously in accordance with the following regimen: once weekly for four weeks during the Induction Phase, once every 7 to 14 days for 6 weeks during the Consolidation Phase, and once every 14 to 28 days until a discontinuation criterion is met during the Maintenance Phase.~MDS cohort 1: Patients will be intradermally administered of DSP-7888 at 10.5 mg every week for 4 weeks, every 2 weeks until Week 24, and then every 4 weeks.~MDS cohort 2: Patients will be intradermally administered of DSP-7888 at 10.5 mg every 2 weeks until Week 24, and then every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSP-7888 Dosing Emulsion
Description: Dose escalation cohort: Patients will be administered escalating doses of DSP-7888 Dosing Emulsion intradermally or subcutaneously in accordance with the following regimen: once weekly for four weeks during the Induction Phase, once every 7 to 14 days for 6 weeks during the Consolidation Phase, and once every 14 to 28 days until a discontinuation criterion is met during the Maintenance Phase.~MDS cohort 1: Patients will be intradermally administered of DSP-7888 at 10.5 mg every week for 4 weeks, every 2 weeks until Week 24, and then every 4 weeks.~MDS cohort 2: Patients will be intradermally administered of DSP-7888 at 10.5 mg every 2 weeks until Week 24, and then every 4 weeks.
Study: NCT03891810

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Calm
Description: The intervention ran for 8-wks with a 4-wk follow-up period. Intervention participants completed 7 days of Calm during Week 1. For the remaining weeks (Week 2- Week 8) intervention participants were asked to meditate during the weekday from a 10-minute meditation of their choice. Throughout the intervention, the Calm College group were sent reminder texts/emails via Google Voice to participate in the meditation sessions if participants are not meditating for more than 30 minutes a week (see Participant Scripts).
Study: NCT03579836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEY1107
Description: Take orally with water once a day on a 3-weeks-on (21 days) continuously and 1-week-off (7 days) schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEY1107
Description: Take orally with water once a day on a 3-weeks-on (21 days) continuously and 1-week-off (7 days) schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEY1107
Description: Take orally with water once a day on a 3-weeks-on (21 days) continuously and 1-week-off (7 days) schedule.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administer 1,000 mg/m2 of Gemcitabine intravenously for 30 minutes on Day 1, 8, 15 and 1-week-off (7days) schedule.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administer 1,000 mg/m2 of Gemcitabine intravenously for 30 minutes on Day 1, 8, 15 and 1-week-off (7days) schedule.
Study: NCT03934268

Intervention type: GENETIC
Intervention: KCNQ2
Description: The researchers extracted DNA from the baby's serum and sent it to WES to get the baby's total exon sequence.
Study: NCT00684216

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hormonal treatment (tamoxifen, exemestane, anastrozole or letrozole)
Description: either tamoxifen or aromatase inhibitor (exemestane, anastrozole or letrozole), QD, until progression of disease
Study: NCT01854801

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individual medical Care
Description: Individual medical care in occupational and environmental diseases centers

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individual electromagnetic exposures
Description: During 7 days, patient hold a dosimeter measuring their electromagnetic exposures for FM, TV, GSM, DECT, WIFI, TETRA and relay antenna emissions. During this week, patients notify intensity and time of their symptoms on a self-questionary
Study: NCT03797573

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: tDCS will be applied during 20 minutes with a current of 1 mA preceded and followed by a behavioral assessments (Modified Ashworth Scale and Coma Recovery Scale Revised) and an EEG. The anodes will be placed over F3 and F4 and the cathodes over C3 and C4.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: Indentical to the active tDCS, except that the stimulation is terminated after 5 seconds.
Study: NCT00542958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NK012
Description: 9.0, 12.0, 16.0, 21.0, 28.0 mg/m\^2, and to be determined. Intravenous infusion
Study: NCT02476500

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LLETZ on a training model
Description: LLETZ is performed on a sausage-based training model using all surgical devices used in the original procedure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LLETZ on a training model
Description: LLETZ is performed on a sausage-based training model using all surgical devices used in the original procedure
Study: NCT02677402

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immersion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immersion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immersion
Study: NCT03821688

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SAS-JB
Description: single anastomosis sleeve jejunal bypass

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OAGB
Description: one anastomosis gastric bypass

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LSG
Description: laproscopic sleeve gastrectomy
Study: NCT02494947

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: high intensity interval-based aerobic exercise
Description: Interval exercises done 3 times weekly during 6 months according to standard procedures at the Department of Circulation and Medical Imaging.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Study: NCT00429091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-894
Description: Subjects will take 1 mg QD, 2 mg QD, 4 mg QD, 4 mg BID for up to four weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atomoxetine
Description: Subjects will take 40 mg BID or placebo for up to four weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subjects will take BID for up to four weeks
Study: NCT06479746

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional support
Description: Emotional support helps the woman giving birth effectively, meets her emotional needs and expectations, ensures her comfort, improves birth outcomes, increases her self-esteem, ensures a positive birth experience and facilitates her transition into the role of motherhood.
Study: NCT02148731

Intervention type: OTHER
Intervention: Frailty markers
Description: Brief screening assessment, CGA and frailty markers will be evaluate at inclusion. CGA and frailty markers will be evaluated at 3, 6, 12 and 18 months after the beginning of chemotherapy. Criteria for toxicity and adverse outcomes will be recorded at each cycle or visits
Study: NCT02406742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-122
Description: CC-122 will be administered daily starting at Cycle 1 Day 1 in 28-day cycles until disease progression, unacceptable toxicity, or discontinuation for any other reason.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-122
Description: CC-122 will be administered daily starting at Cycle 1 Day 1 in 28-day cycles until disease progression, unacceptable toxicity, or discontinuation for any other reason.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-122
Description: CC-122 will be administered daily starting at Cycle 1 Day 1 in 28-day cycles until disease progression, unacceptable toxicity, or discontinuation for any other reason.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab will be administered as an intravenous (IV) infusion at a dose of 100 mg on Cycle 1 Day 1 and 900 mg on Cycle 1 Day 2 and 1000 mg on Cycle 1 Days 8 and 15. The dose of obinutuzumab on Days 1 and 2 of Cycle 1 may be adjusted per institutional practice as long as the combined dose equals 1000 mg. Obinutuzumab will be administered at a dose of 1000 mg on Day 1 of Cycles 2 through 6.
Study: NCT01031134

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shared Decision Making
Description: Shared decision-making, in contrast to traditional medical decision-making, involves a collaborative process where patients discuss personal values and preferences and clinicians provide information to arrive at an agreed upon treatment decision. The focus of the intervention is to empower elderly depressed primary care patients and help them efficiently arrive at a treatment decision that can be successfully implemented.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual Care reflects the standard of care in primary care practice: following physician recommendation for treatment. Physicians will recommend some form of depression treatment. This may take the form of an antidepressant prescription or psychotherapy referral. The physician will encourage patients to telephone with any questions. Following the treatment recommendation provided to the patient, the physician will provide care as usual.